Polina A. Sholkina

Polina A. Sholkina

Auto-generated profile, based on publicly available information

Polina A. Sholkina

V.A. Nasonova Research Institute of Rheumatology

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
APAlena Potapova
Alena Potapova
AKAndrei Karateev
Andrei Karateev
EPE. Yu. Polishchuk
E. Yu. Polishchuk
PSP. A. Sholkina
P. A. Sholkina
EFE. S. Filatova
E. S. Filatova
ALAleksandr M Lila
Aleksandr M Lila
Central sensitization (CS) is a pathophysiological phenomenon that plays a fundamental role in the development of chronic pain and fibromyalgia. The presence of CS can significantly worsen the condition of patients with rheumatoid arthritis (RA) and reduce the response to antirheumatic therapy.The aim of the study – to evaluate the effect of central sensitization on satisfaction in patients with rheumatoid arthritis.Material and methods. The study group consisted of 521 patients with a reliable diagnosis of RA (ACR/EULAR (American College of Rheumatology / European Alliance of Associations for Rheumatology) 2010 criteria), 82.3% of women, 52.0±14.3 years old, with moderate and high disease activity (DAS28-CRP (Disease Activity Score with C-reactive protein) – 4.7±1.0), observed at the clinic of the V.A. Nasonova Research Institute of Rheumatology in 2021– 2022. During hospitalization, all patients underwent correction of the individual therapeutic regimen. At the time of discharge, therapy with genetically engineered biologic DMARDs or Janus kinase inhibitors (JAKi) was continued, induced or modified in 364 patients (69.8%). The presence of a CS was determined by the CSI (Central Sensitisation Inventory) and painDETECT questionnaires. Satisfaction with their condition was assessed during a telephone survey using the PASS index (patient acceptable symptom state) 6 months after discharge from the hospital.Results. Signs of CS according to the CSI questionnaire (≥40 points) were noted in 56.0%, according to the pain- DETECT questionnaire (>18 points) – in 22.5% of patients. A telephone survey was conducted after 6 months in 473 patients (90.8%). 52.0% of respondents considered their condition acceptable (PASS “+”). PASS “+” was significantly more common in patients receiving biologic DMARDs or JAKi, compared with those receiving only synthetic (s) DMARDs: 65.0% and 33.6% (p<0.001). In patients with signs of CS according to CSI, the PASS index “+” was noted in 41.7%, without signs of CS in 65.0% (p<0.001), with signs of CS according to painDETECT, the PASS index “+” was noted in 40.6%, without signs of CS in 55.6% (p<0.001). A significantly lower frequency of PASS “+” was observed in patients with CS both on the background of taking biologic DMARDs or JAKi, and on the background of taking only sDMARDs.

24 June 2026 in Modern Rheumatology Journal
Verified
Journal Article
Closed access
Anastasiia A. ShumilovaAnastasiia A. Shumilova
Anastasiia A. Shumilova
FCFariza Alanovna Cheldieva
Fariza Alanovna Cheldieva
PSP. A. Sholkina
P. A. Sholkina
KNK. S. Nurbaeva
K. S. Nurbaeva
Tatiana Magomedalievna ReshetnyakTatiana Magomedalievna Reshetnyak
Tatiana Magomedalievna Reshetnyak

29 October 2025 in Systemic Hypertension
Verified
Journal Article
Open access
PDF file
AOA. V. Ostraukh
A. V. Ostraukh
AZA. V. Zorin
A. V. Zorin
TVT. N. Veselova
T. N. Veselova
NDN. M. Danilov
N. M. Danilov
TMTamila V. Martynyuk
Tamila V. Martynyuk
Tatiana Magomedalievna ReshetnyakTatiana Magomedalievna Reshetnyak
Tatiana Magomedalievna Reshetnyak
Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening form of pulmonary hypertension, caused by obstruction of the large and/or medium pulmonary arteries by organized thrombi. Currently, a multimodal approach, including surgical and endovascular treatment, using modern specific drugs has improved treatment results. This clinical case demonstrates the successful treatment with triple PAH-specific therapy and balloon angioplasty of the pulmonary arteries in the patient with severe CTEPH associated with systemic lupus erythematosus and antiphospholipid syndrome.

18 October 2025 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
PSP. A. Sholkina
P. A. Sholkina
Anastasiia A. ShumilovaAnastasiia A. Shumilova
Anastasiia A. Shumilova
Tatiana Magomedalievna ReshetnyakTatiana Magomedalievna Reshetnyak
Tatiana Magomedalievna Reshetnyak
This review discusses indices used to assess systemic lupus erythematosus (SLE) activity. Particular attention is given to the definitions of low disease activity and remission in SLE, first clearly formulated in 2016 and 2021, respectively, and to the treat-to-target (T2T) strategy aimed at reducing disease activity, preventing organ damage, and minimizing glucocorticoid use.

1 November 2025 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
PSP. A. Sholkina
P. A. Sholkina
Anastasiia A. ShumilovaAnastasiia A. Shumilova
Anastasiia A. Shumilova
ETE. I. Travkina
E. I. Travkina
LSL. A. Semenova
L. A. Semenova
Tatiana Magomedalievna ReshetnyakTatiana Magomedalievna Reshetnyak
Tatiana Magomedalievna Reshetnyak
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that affects many organs and is characterized by a complex interaction of immune cells, factors and pathways leading to various clinical manifestations. During the disease duration, skin involvement occurs in about 75–80% (up to 20–25% in the debut) of patients with SLE. This article describes two clinical cases with rare chronic skin involvement in patients with SLE.

30 August 2026 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
Anastasiia A. ShumilovaAnastasiia A. Shumilova
Anastasiia A. Shumilova
PSP. A. Sholkina
P. A. Sholkina
KNK. S. Nurbaeva
K. S. Nurbaeva
Tatiana Magomedalievna ReshetnyakTatiana Magomedalievna Reshetnyak
Tatiana Magomedalievna Reshetnyak
АША. А. Шумилова
А. А. Шумилова
ТРТ. М. Решетняк
Т. М. Решетняк
Effective management of systemic lupus erythematosus (SLE) requires close collaboration between physicians and patients, including an adequate level of disease-related knowledge. The aim of this study – to present the results of SLAKE (Systemic Lupus Erythematosus Essential Knowledge Assessment Score) implementation in patients with systemic lupus erythematosus in the Russian Federation and to compare them with an international cohort. Methods . In the first stage, using a crowdsourcing approach, rheumatology experts from the European Reference Network for Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET), together with patients, identified the key knowledge domains related to SLE. Based on these domains, a digital platform was developed to assess patient knowledge. Participants completed a questionnaire consisting of 44 items selected from the SLAKE question bank, covering 11 knowledge domains. The study was conducted online, and demographic as well as clinical characteristics of the participants were collected. Upon completion of the assessment, a total SLAKE score (maximum 44 points) and domain-specific scores for each of the 11 domains (range 0–4 points) were calculated. Participants also received personalized feedback and were asked to evaluate the usability of the platform. Overall, 1,839 patients with SLE were included in the SLAKE analysis and subsequently divided into two groups: Group 1 comprised patients from the Russian Federation (n=214), while Group 2 consisted of patients from other countries (international cohort; n=1,625). Results. The overall SLAKE score did not differ between patients from the Russian Federation and those from other countries. However, significant differences were observed in specific knowledge domains. Patients from the Russian Federation achieved higher scores in the “Disease monitoring” domain, whereas lower scores were recorded in the “Symptoms recognition” and “Non-pharmacological management” domains. Despite a shorter disease duration and lower participation in educational programs, the overall level of disease-related knowledge among Russian patients was comparable to that observed in the international cohort. Conclusions. SLAKE demonstrated high acceptability among patients and may serve as a useful tool for identifying knowledge gaps and tailoring patient education programs to individual needs.